ND-016

N/A

Report date: 2026/03/19 17:03:27

Base Information

Drug NameND-016
Drug Alias NameND-016
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionInterleukin-17 inhibitorsT lymphocytes inhibitorsTumor necrosis factor α inhibitors +[5] 
TargetsInterleukin-17Tumor necrosis factor αInterleukin-5 receptor subunit alpha +[4] 
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNumab Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesIntarcia Therapeutics IncNumab Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A